BioCryst Pharmaceuticals | BCRX - Trade Debtors


BioCryst Pharmaceuticals reported $110.76M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Chugai Pharma JPY 381.9B 28.96B Jun/2026
Daiichi Sankyo JPY 676.92B 19.03B Jun/2026
DBV Technologies USD 15.1M 1.05M Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Incyte USD 1.13B 73.7M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novavax USD 106.45M 72.27M Dec/2025
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026